Clearmind Medicine Inc. announced on June 22, 2026, the completion of Part A treatment in its FDA-regulated Phase I/II clinical trial. This milestone represents a significant progression in the company's clinical development program. Clearmind Medicine is a biopharmaceutical company focused on developing medicines for mental health disorders.
